Detalhe da pesquisa
1.
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma.
N Engl J Med
; 388(9): 813-823, 2023 Mar 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36856617
2.
The current state of molecular testing in the treatment of patients with solid tumors, 2019.
CA Cancer J Clin
; 69(4): 305-343, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31116423
3.
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
Lancet
; 403(10427): 632-644, 2024 Feb 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38246194
4.
A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis.
Oncologist
; 26(3): e505-e507, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-33225544
5.
Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies.
Cancer
; 124(2): 297-305, 2018 01 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29023643
6.
Predictive biomarkers for checkpoint inhibitor-based immunotherapy.
Lancet Oncol
; 17(12): e542-e551, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27924752
7.
Advances in immunotherapy for melanoma.
BMC Med
; 14: 20, 2016 Feb 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-26850630
8.
Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.
Mol Cell Proteomics
; 13(7): 1844-54, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24760959
9.
Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
Proteomics
; 15(2-3): 327-39, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25339196
10.
p75 neurotrophin receptor cleavage by α- and γ-secretases is required for neurotrophin-mediated proliferation of brain tumor-initiating cells.
J Biol Chem
; 289(12): 8067-85, 2014 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24519935
11.
LINAC-based stereotactic radiosurgery to the brain with concurrent vemurafenib for melanoma metastases.
J Neurooncol
; 122(1): 121-6, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25519302
12.
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?
Clin Adv Hematol Oncol
; 13(7): 451-8, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-26353041
13.
Choice of first-line therapy in metastatic melanoma.
Cancer
; 125(5): 666-669, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30695110
14.
Reply to Improving the survival of patients with American Joint Committee on Cancer stage III and IV melanoma.
Cancer
; 124(10): 2254-2255, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29543319
15.
Novel treatments for melanoma brain metastases.
Cancer Control
; 20(4): 298-306, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24077406
16.
Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study.
Cancer Res Commun
; 3(12): 2572-2584, 2023 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38115208
17.
Multi-omic profiling reveals discrepant immunogenic properties and a unique tumor microenvironment among melanoma brain metastases.
NPJ Precis Oncol
; 7(1): 120, 2023 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964004
18.
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
J Immunother Cancer
; 11(10)2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37852736
19.
Transcriptional Profiling of Malignant Melanoma Reveals Novel and Potentially Targetable Gene Fusions.
Cancers (Basel)
; 14(6)2022 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35326655
20.
First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response.
Clin Cancer Res
; 28(17): 3695-3708, 2022 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35511938